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ABSTRACT
Silver nanoparticles (NP) offer many applications in the science and technology. Oral delivery of such tiny particles results in enhanced drug absorption, 
reduction in dose, and minimize adverse effects. This review focuses on the mainly on the effects in the gastrointestinal tract along with its in vitro 
and in vivo studies carried on the silver NP. In this review, we compiled some of the extensive research in the field of silver NP, highlighting some of the 
most recent trends in the area. Search was carried in English language using Science direct, PubMed, and Google scholar search engines. The effects 
of silver NP on gastrointestinal tract such as absorption, distribution, metabolism, and elimination were compiled in this review. In addition, selected 
in vitro and in vivo studies related to the same are discussed. The accumulation of silver NP leading to Arginia condition also emphasized in the study. 
Silver NP and herbal silver NP in oral delivery can be exploited for the further safer and effective treatment.
Keywords: Nanoparticles, Herbs, Silver, Gastrointestine, Drug absorption, Arginia.
INTRODUCTION
Oral drug administration has got several benefits over other routes of 
administration. This route is non-invasive, safer, comfortable, do not 
require skilled person to administer, dose adjustment can be tailor 
made to suit individual patient and hence it is most patient compliant. 
Despite of these facts, oral drug delivery posses’ big challenges to gain 
efficient therapeutic results, this is due to the multitude of biological 
barriers that are present at some point of the gastrointestinal (GI) tract 
that a drug carrier ought to navigate through [1]. Some of enzymes 
present in drug delivery biological path inside the stomach having 
strong acidic pH environment, which degrade the capsules to useless, 
and results in the inefficient penetration of medication across GI tissue 
obstacles, into systemic move, the eventual clearance of medication 
through the GI tract, which can also occur prior to drug release [2]. To 
overcome these barriers, the delivered dosage of medication is often 
more than required therapeutically. However, it is far vital that the 
drug concentration need not exceed the level that could motive toxicity 
within the body, as has been observed with a few DNA and protein 
based totally drugs above critical concentrations. On the other hand, if a 
drug at a non-toxic awareness level passes the physiological barriers of 
the GI tract, its delivered dosage may not be effective [3].
NANO PARTICLES (NP)
NP are known as colloidal system made from solid polymers that may 
be classified with their length and practice processes. They are smaller 
than 1 μm (submicronic particles) and the objects ranging in length 
ranging 1–100 nm, that due to their size may additionally fluctuate 
from the bulk material [4]. Nanosized inorganic particles are of both 
easy or complicated nature, show particular physical and chemical 
properties [5]. NPs have drawn increasing interest from each department 
of medication for their capacity to supply drugs in the ultimate dosage 
range regularly resulting in multiplied healing performance of the pills, 
weakened side outcomes, and improved patient compliance [6]. NP 
have a large surface location to volume ratio, which allows them to soak 
up excessive portions of drugs and to be unfold without problems at 
some stage in the bloodstream [7]. Nanotechnology is anticipated to 
have an impact on medication. The utility of the technology used for 
analysis, treatment, tracking, and manipulate of biological systems 
is now frequently called nano-medicine. In medicine, the usage of 
numerous nanomaterials as pharmaceutical delivery structures for 
drugs, DNA, and imaging agents has gained growing interest. NPs 
showed characteristic colors and properties with the variation of 
size and shape, which can be utilized in bioimaging applications [8]. 
Encapsulation in a NP may added partly defend the contents from the 
degrading surroundings within the stomach and GI tract but peristalsis 
appreciably limits their retention. Bioavailability of NP-mediated oral 
delivery subsequently poor and optimization is needed, permitting 
adequate space for improvement [9].
METALLIC NP
Metallic NPs are in basic terms manufactured from the metals 
precursors. Because of Localized Surface Plasmon Resonance 
characteristics, these NPs own specific optoelectrical homes. NPs of the 
alkali and noble metals, that is, Cu, Ag, and Au have a vast absorption 
band in the visible region of the electromagnetic solar spectrum [10]. 
The facet, length, and shape controlled synthesis of steel NPs is crucial 
in contemporary substances. Due to their superior optical properties, 
metallic NPs locate applications in lots of research areas [11].
SILVER NP
Silver NP (Ag-NPs or Nano-Silver) have attracted increasing interest 
due to their unique bodily, chemical, and biological properties as 
compared to their macro-scaled opposite numbers [12]. Silver ions 
(Ag+) are dissociated from distinct salts and from particulate silver, 
Ag-NPs have exceptional physical chemical properties, including a 
excessive electrical and thermal conductivity, Raman scattering, the 
lowest melting and boiling points, chemical stability, catalytic hobby, 
and non-linear optical behavior [13]. Moreover, silver is the maximum 
reactive of the “noble” metals, and its cations exert poisonous results 
against numerous microorganisms. Silver in shape of NPs discovered 
even extra specific houses, which permits them to be applied inside 
in a couple of fields of method and medicinal drug: solar electricity 
harvesting [14]. The suspensions of silver NP of nano-length or more 
is natural in concept, but in practice be the combinations of silver 
ions, medium sized NP and excited NP. Silver NP are one of the most 
attractive nanomaterials for commercialization applications.
© 2021 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/
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SYNTHESIS OF SILVER NP
Different methods such as organic synthesis, chemical, and physical, the 
AgNPs are obtained. The method of chemical reduction of silver salts 
is the common method following in the synthesis of AgNPs. Among 
silver salts, silver nitrate is very often used due to its cost and strong 
chemical properties. When silver nitrate is reduced to AgNPs, due to 
reduction response, brown color appears and with the reluctant such 
as hydrogen, citrate, and borohydride [15].
In the above case, without decomposition of AgNPs, borohydride acts 
as a strong reducing agent, also reduces the size of NPs when compared 
to glucose. The other biological method to synthesize AgNPs is Green 
synthesis in which as reducing and stabilizing agent sodium alginate 
is used [15].
Due to the instability nature of AgNPs, it always obtained at low yield. 
The aggregation and oxidation are the two factors used to determine 
the stability of AgNPs. Hence, capping agents such as surfactants with 
ligands, polymers with functional groups such as polyvinylpyrrolidone, 
polyethylene glycol and polymethyl methacrylate are used to increase 
the stability of AgNPs. [15]. Plant sources such as leaves of aloevera, 
Citrullus colocynthis, Ocimum sanctum, Cinnamomum camphora, and 
geranium are used to synthesize NPs. Herein, the authors synthesized 
the NPs by green synthesis technology by incorporating curcumin from 
Curcuma longa as natural reducing agent [16].
PREPARATION OF NP
For the preparation of NP, the choice of the appropriate method is based 
totally at the drug to be loaded and physicochemical properties of the 
polymer. The primary preparation method of NP consists of:
 a. Emulsion-Solvent Evaporation Method
 b. Double Emulsion and Evaporation Method
 c. Salting Out Method
 d. Emulsion Diffusion Method
 e. Solvent Displacement/Precipitation Method [17].
GI TRACT
To incorporate the NPs in GI tract, two important methods are there, they 
are, exogenous, and endogenous. It was reported that, in endogenous 
method, the NPs resources are calcium and phosphate secretion of 
gut. In exogenous method, NPs sources are food, water, cosmetics, and 
pharmaceuticals [18]. In food industries especially in the preparation 
of sauce, dressings, the titanium dioxide, silicates, or alumina-silicates 
are widely used. The above said type of NP of spherical in shape and 
approximate size 100 nm is showed resistivity to degradation. The 
NP known as endogenous particles such as calcium and phosphorous 
which are re-circulate inside the gut environment [18] and also the skin, 
lungs and GI tract are considered as the major routes of NP  [19]. The 
routine way of entering into the GI tract is nutritional micro and NP. The 
advanced nano-technology techniques improved the customized NP 
based drugs for more absorption in the GI tract [20]. Other than the above 
said methods, NP may enter into the GI tract by various methods such as 
ingested using food, water, drugs and cosmetics, and inhalation [20]. If 
the particle size is much smaller, it can effortlessly diffuse within the GI 
secretions and join the blood flow and translocate [20].
It is one of the critical tasks for the uptake or ingestion of particles 
and molecules in GI. Oral drug transport systems are having more 
complicated barrier-exchange systems for insertion and transport 
of molecules and their absorption inside the intestine. The oral 
drug delivery system is more tough and complicated because of 
low solubility, low apparent permeability, and low bioavailability 
by means oral chemotherapy [21]. Nanotechnology enables the 
researchers/scientists to monitor out the barriers of conventional path 
procedures and is feasible to supply the focused hydrophobic, precise 
drugs to particular regions of GI tract; transcytosis of medication and 
intracellular transport of drugs [22].
BARRIERS TO ORAL DELIVERY OF NPS
For oral transport of NPs, factors such as acid media of GI tract, GI 
environment, digestive enzymes, and tight enzymes are considered 
as barriers. The gradual increase or change of pH range in stomach, 
intestine is also acts as barriers for NPs. This varied pH inside the GI 
tract makes tough to keep NP integrity during its stay and journey. The 
stomach consists of strong hydrochloric acid and enzyme pepsin, which 
plays a big role in degrade of proteins [23]. The duodenum of the small 
gut contains bile salts and degradative enzymes, play a powerful role in 
degrade/breakdown starch, fat, and proteins, respectively. Other bodily 
contents such as pancreatic juices comprising pancreatin, trypsin, 
lipase, peptidases (breaks peptide bonds), and maltase (degrades 
maltose) helps in breakdown of NPs. All of these degradative enzymes 
present bold boundaries for the oral delivery of proteins, nucleic acids, 
or drugs [24].
The mucus layer that traces the surface of the GI tract can gift every 
other barrier to delivery and also in speedy NP clearance. However, a 
few NP are provided an effort to open the tight junctions and enhance 
delivery which is useful in keeping shipment integrity due to the lack 
of proteolytic encounters when shipping occurs through the tight 
junctions [25].
OVERCOMING ORAL DELIVERY BARRIERS WITH USE OF NP
Using NP, one can protect drug, peptide, or nucleic acid contents 
from degradative enzymes, accelerated mucoadhesion, and extended 
retention within the GI tract. It also enhancing the oral delivery of 
poorly adsorbed tablets, proteins, and nucleotides by increasing the 
interaction period with the mucus layer of the intestine [26]. It is 
understood that the elevated mucosal interplay is because of positively 
charged NP and the negatively charged mucus electrostatic interactions 
and endothelial layer [27]. It was reported that, NPs have mucoadhesive 
houses by the usage of mucoadhesive polymers, which includes 
Eudragit, poly(acrylic acid), sodium alginate, chitosan, and the like [28]. 
Although the mucoadhesive properties of NPs are beneficial, it end up 
relation if loosely connected mucus layer that is unexpectedly shed 
using the stomach. By engineering, we can mask the cargo nature and 
enhance the delivery shipment through each of the cellular membrane 
such as epithelial layer by altering the size, rate, and other qualities of 
the NP [29].
ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION 
(ADME)
Absorption
The absorption while in oral administration both in human and different 
mammals has been defined qualitatively in various investigations. Few 
studies providing statistics regarding quantitative analysis are used to 
analyze the orally administered radionuclide of silver (as silver nitrate) 
and silver excretion in numerous species [30]. The following are the 
fecal excretion values such as 99.6% for mice, 98% for rats, 90% for 
puppies, and 94% for monkeys. Silver can be absorbed after excreted 
through the bile, and the information suggest that absorption ranges 
from 0.4% to 10% depending at the species, such as 10% and 6% for 
dogs and monkeys, respectively [31]. It was investigated and reported 
that, silver retention in a 43-year vintage female orally administered 
with Silver NP, who already suffered from argyria, with the usage of 
a radioactive tracer, silver retention turned into observed to be 18%. 
While comparing ionic silver and nanoparticulate silver after oral 
administration, the latter become shown to be less bioavailable based 
totally on better fecal excretion and lower absolute levels in organs 
following head to head investigations [32].
Distribution
The ionic and nanoparticulate silver which are orally administered had 
been deposited in a huge range of organs. The maximum nicely defined 
depositional impact is the blue–grey discoloration of the human pores 
and skin that is observed at some point of argyria [33]. In addition 
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to pores and skin, silver deposition has also been detected in several 
organs during oral administration, such as liver, kidneys, brain, pores 
and skin, spleen, pelt, eyes, blood, small intestine, muscular tissues, 
stomach, bladder, lungs, tongue, prostate, teeth, thyroid, parathyroid, 
coronary heart, salivary gland, duodenum, and pancreas and in the 
kidneys, it is deposited inside the glomerular basement membrane. In 
the oral administration of Silver NPs, silver does cross the blood–brain 
barrier to enter the brain extracellular fluid; however, it is deposited in 
its lining [34]. It was reported that, in the brain of a 72 year-old woman 
silver is stricken by Argyria, but, no silver was located inside the central 
nervous parenchyma and determined the switch of silver from mothers 
to offspring following an oral dose of 250 mg/kg of bw/day of 8 nm 
silver NP, suggesting that silver can move the placental barrier [35]. In 
other studies, the oral administration of 14 nm silver NP at an equivalent 
dose resulted in a similar pattern of distribution, despite the fact that 
lower amounts have been found inside the lungs, muscle, plasma, and 
brain compared to ionic silver [36].
In comparison an oral dose of 9 mg of ionic silver/kg of bw/day (as 
silver nitrate) with an oral dose of 90 mg of nanoparticulate silver/kg of 
bw/day for 28 days (the NP sizes had been 15 and 20 nm), and noticed 
similar outcomes [36].
Metabolism
It has been reported that, silver particles can be deposited at pores of 
tissues and skin epidermis, glomeruli and in intestine. In vivo studies 
showed that, the debris of the rat intestine contains silver along with 
selenium and sulfur and the diameter of the debris is 12 nm [37]. It 
was reported that, the silver particles comprise selenium deposited 
in human Argyria. It was noticed that, the silver particle noticeable 
deposition both in quantity and length in rat eyes for the duration of 
the primary weeks of administration. It was also reported that, after 
withdrawn of silver for about 12 months, it was noticed that the length 
of silver NP is reduced. It has been reported that, the ionic silver or 
silver present in the suspension is being deposited but not the whole 
particle’s being deposited [38].
Excretion
Fecal excretion
In fecal excretion rate of silver particles was studied in which, the 
usage of the one hundred ten radionuclide of silver in several animal 
species, has discovered and reported the fecal excretion rates, which 
are 99.6% for mice, 98% for rats, 90% for dogs, and 98% for monkeys. 
In oral and non-oral administration bile duct studies, due to silver 
accumulation in liver, the excretion of the absorbed silver was faded 
and whereas non-oral investigation it was reported that 50% of an 
infused dose of silver can be recovered inside the rat bile [39]. It shows 
that, oral administration is better for 14 nm silver NP than for ionic 
silver; namely, 63% and 49% for NP and ionic silver. This explains the 
lower bioavailability of silver NP [40].
Urinary excretion
The urinary excretion at 12 h in a woman turned into within the range of 
2–4, 104% of an orally administered dose of a radioactive silver tracer, 
a constrained amount of the orally administered 110 radionuclide of 
silver became excreted in the urine. The urinary fecal excretion ratios 
were such as 0.001 (mice), 0.001 (rats), 0.019–0.26 (monkeys)m and 
0.012–0.061 (dogs). About 0.012% and 0.057% of administered silver 
within the urine following the oral administration of 14 nm silver NP 
and silver acetate [41]. The detected silver inside the rat urine following 
the oral administration of 1 mg/kg of bw of 8 nm particles, specifically 
0.042 lg/mL (on this investigation, 378 lg/g become determined in the 
feces) [41].
EFFECT OF SILVER ON BODY WEIGHT
The reports says that, the administration of Silver NPs will retard the 
growth rates in rat model it was administered a 0.25% silver nitrate 
solution for 8 ½ months (this dose corresponds to 81 mg/kg of BW/day), 
when silver administration was withdrawn, the body weight became 
reinstated by a period of 10 weeks. Similar type of report noticed in 
other studies where for the source of silver NP, silver acetate used and 
administered (9 mg of Ag/kg of bw/day) and also in another  13 week 
study of the oral management of 500 mg of 60 nm AgNPs/kg of bw/day 
in rats, showed reduced body weight male mice [42].
EFFECT OF SILVER ON GI TRACT
There are three investigations reports during oral toxicity studies that, 
inside the GI tract they noticed excessive silver deposition where AgNPs 
(of size 5–20 nm) broken the epithelial cellular microvilli and intestinal 
glands after administration for 21 days in mice model [43].
IN VITRO AND IN VIVO STUDIES OF ORAL NANOCARRIERS
In vitro studies
In the development of advanced pharmaceutical pills, the preclinical 
toxicology assessment is an essential step. Before administration of 
drugs to human beings, toxicology study by the way of in vitro and in vivo 
methods so as to make sure the safety of medicaments. Till date, the NPs 
designed for oral delivery purposes studies performed were focused on 
the basis of their functionality via the epithelial membrane and promote 
their efficacy. In many instances, the intestinal membrane permeability 
alterations involved in potential accumulation of the nanocarriers 
inside the body and other consequences were underestimated. In many 
cases, only in vitro tests had been done to examine the toxicity of the 
nano-carrier. In NPs toxicity studies in in vitro models are insufficient 
to guess all possible dangers to human beings and to avoid, a carry of 
hit transition through clinical trials is much required [44]. To analyze 
the nano-toxicity of the nano-carriers a consequent in vitro and in vivo 
studies are required and researchers are recommending the same.
Cytotoxicity studies
In vitro assays based totally on cell way of studies, where very successful 
methods are established to conduct on cells of an organism, which are 
very useful in the screening of NPs and in mechanistic assays.
Cell models
Ideally, using required cell lines related to the target organs is used for 
in vitro studies. For the examination of nano carriers toxicity during oral 
drug delivery carried out in human mobile strains such as enterocytes, 
metabolic activities. Human colon carcinoma derived Caco-2 cells were 
used as a model of intestinal epithelium to examine the toxicity of many 
NPs [45]. The cells may co-cultured with HT29 which is additionally 
derived from human colon carcinoma while developing post confluent. 
These models do the evaluation of mucosa changes in the gel like 
structure. As an option, using primary cultured cells used to avoid 
mobile culture protocols during toxicity assays [46].
In vivo studies
In recent years, even the in vitro models giving feasible information 
which are sufficient in expecting possible risks to humans and to justify 
transition through scientific trials before releasing into the market. 
In vitro results provide statistics and not represent very realistic 
version of the way of NPs will engage with a particular organ of the 
body. For instance, in vitro assays will not reveal enough information 
about the toxic nature of NPs and hence not be good enough for 
figuring out the toxic ability. Consequently, information acquired for in 
vitro studies a final verification required in vivo experiments to assess 
nano-toxicity [47].
As per moral considerations, in vivo studies will do only at final stage for 
confirmation of its nano-toxic or nano-nontoxic nature of NPs because 
of the use and sacrifice of animals. Furthermore, these research studies 
needs long-term consequences, bio-distribution, tissue accumulation, 
and retention/excretion of NPs in a greater way than the in vitro 
models. There are number of interconnected pathways to understand 
in human situation and a single in vitro test cannot reveal everything. 
Toxicity exams are classified into acute, sub-acute, sub-chronic, and 
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continual research. Other factors such as ADME and pharmacokinetics, 
carcinogenic and teratogenic studies are also much required for 
nanomaterial toxicity [48].
To conduct in vivo research it’s essential to understand the overall 
conduct that NPs have to showcase within the organism: (a) route 
of management, (b) targeting and biodistribution residences after 
administration, (c) biodegradation path methods, and (d) eventual 
accumulation in the body. Hence, the knowledge of the physicochemical 
properties of nanocarriers will help in planning for the toxicological 
study [49].
In general, in vivo studies are undertaken in rodents, but in exceptional 
cases, studies with both zebrafish (Danio rerio) or Caenorhabditis 
elegans are also emerged as promising in vivo models for nanotoxicity 
research [50,51]. In vivo NPs toxicity research performed in rodents 
generally focused on (a) clinical signs and symptoms of toxicity, 
(b) adjustments in organ and tissue morphology, examined beneath 
microscopy, (c) changes in blood serum chemistry and cellular 
population, and (d) the general NP bio-distribution [52]. During 
in vitro research, before initiating the studies, consider many factors 
such as NP characterization and desire of the relevant model system. 
For in vivo research, great variant can be delivered because of species, 
pressure, weight loss plan, housing conditions, circadian rhythm 
variations, and endogenous microbiota. To analyze histological or 
serum/hematological adjustments, one must remember problems of 
exposure direction, NP dosing and precise tissue/organ or protein/cell 
type of interest. In the in vivo toxicity studies, it is crucial to confine with 
purity of nanomaterials and also any non-precise toxicity attributed to 
material impurities or organic contaminations may be excluded [53].
As we aware that, majority of nanotoxicity studies has focused on cell 
culture systems, includes complexity of the assays, the cost and the 
low throughput in comparison with the in vitro ones. Standardized 
protocols are also had to perform the in vivo research [54,55].
Toxicity studies
The study of effect of Ag-NPs on human health and environment a 
very less studies have been done though the above NPs are having a 
huge number of applications. Only few research articles are trying 
to enlighten regarding both in vitro and in vivo NP toxicity studies 
which includes consequences, cytotoxic nature, genotoxic effect in 
relevance to the size, length, concentration, time of exposure, and 
environmental elements [56]. Researchers noticed that, the unstable 
nature of NPs in media when it acts or combine with biological 
macromolecules/inorganic molecules/natural ions is due to the surface 
coating agents, amino acids, acetyl trimethyl ammonium bromide, citric 
acid, and sodium dodecyl sulfate are non-covalently attached to the 
nanosilver particles. Many in vivo and in vitro are also shown the toxic 
nature of AgNPs in certain model systems [57]. The whole toxicological 
investigations was done on the basis of the NPs length, shape, surface 
charge chemical composition, solubility, their capability to bind and 
affect organic sites as well as their metabolism and excretion influence. 
Although studies have done, still it is not very clear that, which degree 
the toxicity of AgNPs consequences from released silver ions and kind 
of toxicity is associated with the AgNPs consistent per se. Many authors 
opined that the measured silver ion content of the AgNP suspension 
not completely provide an explanation for the toxicity of the AgNP 
suspension [58,59].
SAFETY OF ORALLY DELIVERED NP
It has been observed an exponential growth in the number of research 
publications about the toxicity of nanomaterials in the recent years. 
However, it remains difficult to come to conclusion by considering 
the others observation about NPs and the potential toxicity of 
nanomaterials. The other factors are the different methodologies, 
subjects, models are also under considerations. The International 
research for Standardization Organization (ISO) has posted several 
requirements which might be relevant for the category of engineered 
nanomaterials. As an instance, ISO/TS 107868:2011 describes the 
characterization of single-walled carbon nano-tubes (SWCNT) using 
UV–Vis, and ISO/TS 10798:2011 describes the characterization of 
SWCNT using Scanning Electron Microscopy and dispersive X-ray 
spectrometry evaluation (www. iso.org). Greater requirements for the 
characterization of the physicochemical properties of nanomaterials 
will appear and consequently permit the contrast and category of 
nanomaterials to be studied.
However, nano-metrology becomes a complicated dynamic nano-scale 
structures common in nanomedicine such as liposomes and polymer-
primarily based micellar entities. Other applicable kinds are drug 
delivery agents that release their cargo of medication [60-62]. Before 
drive the NPs, it is mandatory to outline the bodily traits and numerous 
more strategies have to be implemented to correctly describe length 
and shape. It is reported that the propensity for aggregation might also 
alternate in exceptional solutions including cellular media without or 
with serum and inside the blood stream, and aggregation could have a 
substantial impact on NP toxicity and in vivo clearance mechanisms [63].
Regarding the safety evaluation of nanomedicine, the Nanotechnology 
Characterization Laboratory has provided protocols (www.ncl.most 
cancers.gov). Those assays function needs minimal requirements 
for physicochemical characterization and additionally need well-
characterized reference materials [64]. One such reference is the 
citrate-stabilized gold NP from the National Institute of Standards 
and Technology (NIST). Current studies at NIST (www.nist.gov) are 
directed at producing reference standards for titanium dioxide and 
silver NP. Glaringly the strong, relevant, and synthetically reliable NP 
are taken into consideration as reference materials; also, medically 
applicable reference standards are required. It’s crucial to underscore 
the presence of chemical residues such as catalysts or surfactants that 
provide fake results in toxicity research of nanomaterials [65].
CONCLUSION
The review study provides a detailed information about silver NP about 
its oral administration, which enlightens the exceptional strategies 
using to examine oral delivery of NP, barriers, toxicity, and safety. This 
survey study provides in different model systems like in vitro and in vivo 
studies, cell models and also its toxicity studies.
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